Shows
Patient from HellEpisode 70: Lung Cancer Screening, Stigma, and Science with Dr. Bellinda King-KallimanisIn this episode we speak with Bellinda King-Kallimanis, PhD, an expert in oncology research and patient advocacy. Bellinda shares her diverse experience in the field, from academia to the FDA and now her role at LUNGevity Foundation. The conversation covers various aspects of lung cancer, including screening procedures, risk factors, and common misconceptions. Bellinda emphasizes the importance of early detection and addresses the stigma associated with lung cancer. We also delve into the Patient-Centered Outcomes Research Institute (PCORI) and a study comparing the impact of using different types of material to communicate screening information to patients. The episode also...
2024-08-0741 min
CANCER BUZZPromoting Equitable Care through the 4R Oncology® ModelWhile molecularly targeted therapies based on actionable biomarkers are improving outcomes for patients with lung cancer, access to biomarker testing continues to hinder equitable and comprehensive care for underserved patients. In this episode, CANCER BUZZ TV speaks with Tom Lycan, DO, MHS, assistant professor of Hematology & Oncology at the Wake Forest School of Medicine, about a practical tool that can provide a care plan roadmap for providers and patients to mitigate precision medicine disparities. "[The 4R Care Sequences pathway] gives an overarching view of what they [patients] are looking for in the immediate future and also down t...
2024-06-2705 min
PeerView Heart, Lung & Blood CME/CNE/CPE Audio PodcastLecia V. Sequist, MD, MPH - Screening and Early Intervention as the Keys to Success in Lung Cancer: A Practical Approach to Implementing Lung Cancer Screening for High-Risk IndividualsThis content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/PJP865. CME/MOC/AAPA/IPCE credit will be available until April 16, 2025.Screening and Early Intervention as the Keys to Success in Lung Cancer: A Practical Approach to Implementing Lung Cancer Screening for High-Risk Individuals In support of improving...
2024-05-0747 min
PeerView Internal Medicine CME/CNE/CPE Video PodcastLecia V. Sequist, MD, MPH - Screening and Early Intervention as the Keys to Success in Lung Cancer: A Practical Approach to Implementing Lung Cancer Screening for High-Risk IndividualsThis content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/PJP865. CME/MOC/AAPA/IPCE credit will be available until April 16, 2025.Screening and Early Intervention as the Keys to Success in Lung Cancer: A Practical Approach to Implementing Lung Cancer Screening for High-Risk Individuals In support of improving...
2024-05-071h 03
The Research EvangelistMeet Dr. Upal Basu Roy, Executive Director of LUNGevity Research and a passionate patient-focused project managerOn today's episode, meet Dr. Upal Basu Roy, PhD, MPH. Dr. Basu Roy is the Executive Director at LUNGevity Research where he spearheads LUNGevity’s Translational Research Programs and Patient-Focused Research Center (Patient FoRCe). He has implemented and manages LUNGevity’s patient-focused research including Project Transform, a multi-year, multi-stakeholder patient preference study that LUNGevity is conducting with Johns Hopkins University School of Public Health. Dr. Basu Roy also has extensive experience in community-based participatory research (CBPR) methodology in health sciences research, specifically in projects involving immigrants and minority populations.
Dr. Basu Roy has a PhD in Molecular and...
2024-04-1643 min
BabyMaking 101Kicking Cancer's Butt With BlueFinally my long awaited chat with Lenny Blue, the Stage 4 cancer survivor who not only has beaten the odds, but has turned his challenges into inspiration for others.
This episode discusses cancer treatments, such as immunotherapy, as well as cancer prevention and so much more; but does it all through the eyes of a survivor.
Podcast guest Lenny "Blue" has graciously shared his email address for anyone who would like to connect: survivorhere@outlook.com
The links to the support options discussed in today's episode are:
https://cancerhopenetwork.org for the C...
2024-04-1051 min
Cancer Care ConnectionsUnderstanding the Progression and Treatment of Non-Small Cell Lung CancerDiscover the groundbreaking strides made in the fight against lung cancer as we welcome Dr. Christopher Paschold from Virginia Oncology Associates to share his expertise on the latest in cancer treatment and screening. Our conversation sheds light on the silent progression of non-small cell lung cancer and the critical role early detection plays in improving outcomes. Dr. Paschold emphasizes the importance of proactive screening measures for those at high- risk. We also explore the impact of breakthrough therapies like immunotherapy and targeted therapy treatments, offering new hope to patients. This episode is a resource for anyone touched by lung c...
2024-01-0918 min
The Health Design PodcastEugene Manley Jr., CEO SCHEQDr. Eugene Manley Jr is an inspirational speaker that often speaks about overcoming barriers, mentoring, and STEM and workforce diversity. He is a Mechanical Engineer, Biomedical Engineer, and Molecular and Cell Biologist with expertise in musculoskeletal biology, biomechanics, and cancer biology. He is adept at planning and executing complex systems biology problems, imaging, pathology, and combination drug therapies. Currently he is the Founder and CEO of the STEMM & Cancer Health Equity (SCHEQ) nonprofit foundation that seeks to increase STEMM workforce diversity and improve outcomes for underserved and marginalized populations across the cancer care continuum. He previously worked at LUNGevity where...
2023-12-2130 min
The Light Cellar PodcastLCP #15: Herbal Highlights with Angela Bewick episode 2, Lungevity, Mullein & OreganoWelcome to the second episode in a new weekly series where you will learn about herbs and herbal preparations as Malcolm & Angela sit down to discuss what has come up in their work crafting herbal preparations during the week. In this series we’ll also include updates about specific products as items come in or out of stock and we will be answering your questions. This week, they dive in to three herbs to support lungs. Look for these in-store or online! Let us know if you have any questions and what you th...
2023-12-1115 min
The Parexel PodcastHow can we advance fair and ethical reimbursement for patients?In this podcast, Parexel Vice President of Patient Engagement Rosamund Round leads a discussion on practical challenges and regulatory considerations for patient reimbursement programs in clinical trials. Elizabeth Barksdale, Director of Regulatory Affairs and Scientific Policy for LUNGevity Foundation, a non-profit lung cancer advocacy group, and Luke Gelinas, Senior IRB Chair Director for the global clinical research compliance organization Advarra, advocate for a new framework that fully reimburses patients for travel and compensates them for an additional tier of “soft” costs that will positively impact many patients’ ability to join or remain in a clinical trial, and improve health equity
2023-11-2111 min
Beyond The RibbonLUNGevityLUNGevityLUNGevity is transforming how people are diagnosed and live with lung cancer through research, education, and support.
2023-11-1850 min
Citizen ScienceYou Can Help Medical Researchers Fight Disease! (VIDEO)By donating just a little bit of your time (and maybe some saliva and/or blood), you can make a meaningful contribution to medical research! In this episode, you’ll learn about three participatory research programs that need your help.
Projects and websites included in this podcast include:
SciStarter Project Page: Outbreaks Near Me
Outbreaks Near Me Home Page
LUNGevity Participant Survey
LUNGevity Foundation
SciStarter Project Page: All of Us
All of Us Network of the National Library of Medicine
All of Us: NIH
Join All of Us
SciStarter National Library of Medicine page
SciStarter Libraries Page
Photo Credit: CDC
Mus...
2023-11-1629 min
Citizen ScienceLearn How You Can Help Medical Researchers!By donating just a little bit of your time (and maybe some saliva and/or blood), you can make a meaningful contribution to medical research! In this episode, you’ll learn about three participatory research programs that need your help.
Projects and websites included in this podcast include:
SciStarter Project Page: Outbreaks Near Me
Outbreaks Near Me Home Page
LUNGevity Participant Survey
LUNGevity Foundation
SciStarter Project Page: All of Us
All of Us Network of the National Library of Medicine
All of Us: NIH
Join All of Us
SciStarter National Library of Medicine page
SciStarter Libraries Page
Photo Credit: CDC
Mus...
2023-11-1629 min
The ONS PodcastEpisode 284: How AI Is Influencing Cancer Care and Oncology Nursing"We incorporate nurses and clinicians and users for any tool from the very beginning. They say, 'You know, we need help with this.' And then we start ideation: We start understanding the problem, we meet with them, we try to see what is it that they're trying to do, is it feasible given the data we have? We go back, we do some research, feasibility study. We say we think this is something we can predict with decent performance. Now let's do it," Nasim Eftekhari, MS, executive director of applied artificial intelligence (AI) and data science at the...
2023-11-0340 min
Growth Investor with GrowthCap‘s RJ LumbaPrivate Market Innovation At Scale: Partners Group’s Robert CollinsIn this episode, we speak with Robert Collins of Partners Group, where he serves as Co-Head of Private Wealth, Head of the firm’s New York Office and a member of the Global Executive Board.
Partners Group is a leading global private markets firm. Since 1996, the firm has invested over $200 billion in private equity, private debt, private real estate, and private infrastructure on behalf of its clients.
The firm seeks to generate strong returns through capitalizing on thematic growth trends and transforming attractive businesses and assets into market leaders. Partners Group is a committed, responsible in...
2023-09-1323 min
Pint TalkingStyle Files: American Brown AleIn this episode Bob and I take on an interesting category. We discsuss the American Brown Ale, which in theory looks like a version of the English brown, but jacked up on hops (allegedly). American brown ale with roasted malt, caramel-like and chocolate-like characters should be of medium intensity in both flavor and aroma for the American brown ale. American-style brown ales have evident low to medium hop flavor and aroma and medium to high hop bitterness. The history of this style dates back to U.S. homebrewers who were inspired by English-style brown ales and porters. It sits...
2023-08-2331 min
The American Lung Cancer Screening Initiative PodcastALCSI Podcast: Katie BrownOn this episode of the ALCSI podcast, Katie Brown, a cervical cancer survivor and lung cancer caregiver and advocate discusses her experiences as a caregiver for her father and her work with organizations such as the LUNGevity Foundation, Breathe Deep DFW, and more. Learn more about Katie at iamkatiebrown.com, or on Instagram @iamkatiebrown2. Learn more about ALCSI at www.alcsi.org.
2023-08-2135 minCANCER BUZZThe Role of Nursing in Post-Pandemic Care of SCLC Many patients with small cell lung cancer (SCLC) have a high symptom burden, poor prognosis, and adherence challenges due to treatment-related adverse events, stigmatization, and emotional distress. Multidisciplinary care coordination and timely diagnosis are critical to achieve positive health outcomes for this patient population. Nurses play an important role in the direct care of patients. CANCER BUZZ spoke to Robin Atkins, RN, Symptom Management Triage Nurse, Virginia Oncology Associates in Gloucester, VA. Listen as we discuss nursing's role in the care of patients with small cell lung cancer (SCLC). "What the patient experience means to t...
2023-08-0806 minPeerView Internal Medicine CME/CNE/CPE Video PodcastStephen V. Liu, MD - Amplifying the ADC Advantage: How to Fulfill the Potential of Antibody–Drug Conjugates as the Next Frontier in Precision Lung Cancer CareGo online to PeerView.com/YEN860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Mounting evidence continues to elucidate the clinical potential of antibody–drug conjugates (ADCs) in the treatment of patients with lung cancer. ADCs are now transitioning from research settings to clinical practice, with the first approval of a novel HER2-targeting ADC, trastuzumab deruxtecan, for HER2-mutated NSCLC. In addition, various other potent ADCs targeting HER3, TROP2, CEACAM5, c-MET, AXL, ROR2, and others are being evaluated in clinical trials in different disease settings, including in patients with advanced NSCLC wi...
2023-07-291h 37
PeerView Heart, Lung & Blood CME/CNE/CPE Video PodcastStephen V. Liu, MD - Amplifying the ADC Advantage: How to Fulfill the Potential of Antibody–Drug Conjugates as the Next Frontier in Precision Lung Cancer CareGo online to PeerView.com/YEN860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Mounting evidence continues to elucidate the clinical potential of antibody–drug conjugates (ADCs) in the treatment of patients with lung cancer. ADCs are now transitioning from research settings to clinical practice, with the first approval of a novel HER2-targeting ADC, trastuzumab deruxtecan, for HER2-mutated NSCLC. In addition, various other potent ADCs targeting HER3, TROP2, CEACAM5, c-MET, AXL, ROR2, and others are being evaluated in clinical trials in different disease settings, including in patients with advanced NSCLC wi...
2023-07-291h 37PeerView Heart, Lung & Blood CME/CNE/CPE Audio PodcastStephen V. Liu, MD - Amplifying the ADC Advantage: How to Fulfill the Potential of Antibody–Drug Conjugates as the Next Frontier in Precision Lung Cancer CareGo online to PeerView.com/YEN860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Mounting evidence continues to elucidate the clinical potential of antibody–drug conjugates (ADCs) in the treatment of patients with lung cancer. ADCs are now transitioning from research settings to clinical practice, with the first approval of a novel HER2-targeting ADC, trastuzumab deruxtecan, for HER2-mutated NSCLC. In addition, various other potent ADCs targeting HER3, TROP2, CEACAM5, c-MET, AXL, ROR2, and others are being evaluated in clinical trials in different disease settings, including in patients with advanced NSCLC wi...
2023-07-291h 37
PeerView Clinical Pharmacology CME/CNE/CPE VideoStephen V. Liu, MD - Amplifying the ADC Advantage: How to Fulfill the Potential of Antibody–Drug Conjugates as the Next Frontier in Precision Lung Cancer CareGo online to PeerView.com/YEN860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Mounting evidence continues to elucidate the clinical potential of antibody–drug conjugates (ADCs) in the treatment of patients with lung cancer. ADCs are now transitioning from research settings to clinical practice, with the first approval of a novel HER2-targeting ADC, trastuzumab deruxtecan, for HER2-mutated NSCLC. In addition, various other potent ADCs targeting HER3, TROP2, CEACAM5, c-MET, AXL, ROR2, and others are being evaluated in clinical trials in different disease settings, including in patients with advanced NSCLC wi...
2023-07-291h 37
PeerView Clinical Pharmacology CME/CNE/CPE Audio PodcastStephen V. Liu, MD - Amplifying the ADC Advantage: How to Fulfill the Potential of Antibody–Drug Conjugates as the Next Frontier in Precision Lung Cancer CareGo online to PeerView.com/YEN860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Mounting evidence continues to elucidate the clinical potential of antibody–drug conjugates (ADCs) in the treatment of patients with lung cancer. ADCs are now transitioning from research settings to clinical practice, with the first approval of a novel HER2-targeting ADC, trastuzumab deruxtecan, for HER2-mutated NSCLC. In addition, various other potent ADCs targeting HER3, TROP2, CEACAM5, c-MET, AXL, ROR2, and others are being evaluated in clinical trials in different disease settings, including in patients with advanced NSCLC wi...
2023-07-291h 37
PeerView Oncology & Hematology CME/CNE/CPE Audio PodcastStephen V. Liu, MD - Amplifying the ADC Advantage: How to Fulfill the Potential of Antibody–Drug Conjugates as the Next Frontier in Precision Lung Cancer CareGo online to PeerView.com/YEN860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Mounting evidence continues to elucidate the clinical potential of antibody–drug conjugates (ADCs) in the treatment of patients with lung cancer. ADCs are now transitioning from research settings to clinical practice, with the first approval of a novel HER2-targeting ADC, trastuzumab deruxtecan, for HER2-mutated NSCLC. In addition, various other potent ADCs targeting HER3, TROP2, CEACAM5, c-MET, AXL, ROR2, and others are being evaluated in clinical trials in different disease settings, including in patients with advanced NSCLC wi...
2023-07-291h 37
PeerView Oncology & Hematology CME/CNE/CPE Video PodcastStephen V. Liu, MD - Amplifying the ADC Advantage: How to Fulfill the Potential of Antibody–Drug Conjugates as the Next Frontier in Precision Lung Cancer CareGo online to PeerView.com/YEN860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Mounting evidence continues to elucidate the clinical potential of antibody–drug conjugates (ADCs) in the treatment of patients with lung cancer. ADCs are now transitioning from research settings to clinical practice, with the first approval of a novel HER2-targeting ADC, trastuzumab deruxtecan, for HER2-mutated NSCLC. In addition, various other potent ADCs targeting HER3, TROP2, CEACAM5, c-MET, AXL, ROR2, and others are being evaluated in clinical trials in different disease settings, including in patients with advanced NSCLC wi...
2023-07-291h 37
PeerView Internal Medicine CME/CNE/CPE Audio PodcastStephen V. Liu, MD - Amplifying the ADC Advantage: How to Fulfill the Potential of Antibody–Drug Conjugates as the Next Frontier in Precision Lung Cancer CareGo online to PeerView.com/YEN860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Mounting evidence continues to elucidate the clinical potential of antibody–drug conjugates (ADCs) in the treatment of patients with lung cancer. ADCs are now transitioning from research settings to clinical practice, with the first approval of a novel HER2-targeting ADC, trastuzumab deruxtecan, for HER2-mutated NSCLC. In addition, various other potent ADCs targeting HER3, TROP2, CEACAM5, c-MET, AXL, ROR2, and others are being evaluated in clinical trials in different disease settings, including in patients with advanced NSCLC wi...
2023-07-291h 37
Inside Cancer CareersFellows Who Lead & Pathways to Non-Profit CareersIn this episode, we hear from NIH fellows, Dr. Vasty Osei Amponsa and Dr. Marja Brolinson on resources, leadership opportunities, and more at NIH. We then hear from Dr. Eugene Manley Jr., Director of STEM Initiatives at LUNGevity Foundation who shares his path from bench science to a successful career in non-profit organizations. Segment 1: Fellows Who Lead Vasty Osei Amponsa, Ph.D. NCI Center for Cancer Research - Center for Structural Biology Marja Brolinson, M.D. Todd Macfarlan Lab Eunice Kennedy Shriver National Institute of Chi...
2023-07-2058 minPeerView Oncology & Hematology CME/CNE/CPE Audio PodcastTaofeek K. Owonikoko, MD, PhD - Progress on the Path to Improving Outcomes in the Treatment of SCLC: Making the Most of Current Standard-of-Care Therapies and Exploring New Promising ResearchGo online to PeerView.com/WFE860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Important advances have occurred in the treatment of small cell lung cancer (SCLC) in recent years, and more exciting progress in the form of improved understanding of the disease biology, subtypes, and novel therapies is on the horizon. This educational activity, based on a recent live symposium produced in collaboration with LUNGevity Foundation, offers useful guidance for navigating the evidence supporting the use of current and emerging therapies in SCLC and translating the latest science to everyday clinical...
2023-07-011h 23PeerView Clinical Pharmacology CME/CNE/CPE Audio PodcastTaofeek K. Owonikoko, MD, PhD - Progress on the Path to Improving Outcomes in the Treatment of SCLC: Making the Most of Current Standard-of-Care Therapies and Exploring New Promising ResearchGo online to PeerView.com/WFE860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Important advances have occurred in the treatment of small cell lung cancer (SCLC) in recent years, and more exciting progress in the form of improved understanding of the disease biology, subtypes, and novel therapies is on the horizon. This educational activity, based on a recent live symposium produced in collaboration with LUNGevity Foundation, offers useful guidance for navigating the evidence supporting the use of current and emerging therapies in SCLC and translating the latest science to everyday clinical...
2023-07-011h 23PeerView Internal Medicine CME/CNE/CPE Video PodcastTaofeek K. Owonikoko, MD, PhD - Progress on the Path to Improving Outcomes in the Treatment of SCLC: Making the Most of Current Standard-of-Care Therapies and Exploring New Promising ResearchGo online to PeerView.com/WFE860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Important advances have occurred in the treatment of small cell lung cancer (SCLC) in recent years, and more exciting progress in the form of improved understanding of the disease biology, subtypes, and novel therapies is on the horizon. This educational activity, based on a recent live symposium produced in collaboration with LUNGevity Foundation, offers useful guidance for navigating the evidence supporting the use of current and emerging therapies in SCLC and translating the latest science to everyday clinical...
2023-07-011h 23PeerView Oncology & Hematology CME/CNE/CPE Video PodcastTaofeek K. Owonikoko, MD, PhD - Progress on the Path to Improving Outcomes in the Treatment of SCLC: Making the Most of Current Standard-of-Care Therapies and Exploring New Promising ResearchGo online to PeerView.com/WFE860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Important advances have occurred in the treatment of small cell lung cancer (SCLC) in recent years, and more exciting progress in the form of improved understanding of the disease biology, subtypes, and novel therapies is on the horizon. This educational activity, based on a recent live symposium produced in collaboration with LUNGevity Foundation, offers useful guidance for navigating the evidence supporting the use of current and emerging therapies in SCLC and translating the latest science to everyday clinical...
2023-07-011h 23PeerView Internal Medicine CME/CNE/CPE Audio PodcastTaofeek K. Owonikoko, MD, PhD - Progress on the Path to Improving Outcomes in the Treatment of SCLC: Making the Most of Current Standard-of-Care Therapies and Exploring New Promising ResearchGo online to PeerView.com/WFE860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Important advances have occurred in the treatment of small cell lung cancer (SCLC) in recent years, and more exciting progress in the form of improved understanding of the disease biology, subtypes, and novel therapies is on the horizon. This educational activity, based on a recent live symposium produced in collaboration with LUNGevity Foundation, offers useful guidance for navigating the evidence supporting the use of current and emerging therapies in SCLC and translating the latest science to everyday clinical...
2023-07-011h 23PeerView Heart, Lung & Blood CME/CNE/CPE Audio PodcastTaofeek K. Owonikoko, MD, PhD - Progress on the Path to Improving Outcomes in the Treatment of SCLC: Making the Most of Current Standard-of-Care Therapies and Exploring New Promising ResearchGo online to PeerView.com/WFE860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Important advances have occurred in the treatment of small cell lung cancer (SCLC) in recent years, and more exciting progress in the form of improved understanding of the disease biology, subtypes, and novel therapies is on the horizon. This educational activity, based on a recent live symposium produced in collaboration with LUNGevity Foundation, offers useful guidance for navigating the evidence supporting the use of current and emerging therapies in SCLC and translating the latest science to everyday clinical...
2023-07-011h 23PeerView Clinical Pharmacology CME/CNE/CPE VideoTaofeek K. Owonikoko, MD, PhD - Progress on the Path to Improving Outcomes in the Treatment of SCLC: Making the Most of Current Standard-of-Care Therapies and Exploring New Promising ResearchGo online to PeerView.com/WFE860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Important advances have occurred in the treatment of small cell lung cancer (SCLC) in recent years, and more exciting progress in the form of improved understanding of the disease biology, subtypes, and novel therapies is on the horizon. This educational activity, based on a recent live symposium produced in collaboration with LUNGevity Foundation, offers useful guidance for navigating the evidence supporting the use of current and emerging therapies in SCLC and translating the latest science to everyday clinical...
2023-07-011h 23PeerView Heart, Lung & Blood CME/CNE/CPE Video PodcastTaofeek K. Owonikoko, MD, PhD - Progress on the Path to Improving Outcomes in the Treatment of SCLC: Making the Most of Current Standard-of-Care Therapies and Exploring New Promising ResearchGo online to PeerView.com/WFE860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Important advances have occurred in the treatment of small cell lung cancer (SCLC) in recent years, and more exciting progress in the form of improved understanding of the disease biology, subtypes, and novel therapies is on the horizon. This educational activity, based on a recent live symposium produced in collaboration with LUNGevity Foundation, offers useful guidance for navigating the evidence supporting the use of current and emerging therapies in SCLC and translating the latest science to everyday clinical...
2023-07-011h 23
Girl Doc Survival GuideEP52: My awesome friend, and lung cancer survivor, Bess Siegal!The experience of being a patient is inextricably linked to the experience of being a doctor. Bess Siegal is one of my longest term friends (she's known me over half of my life!), and she was diagnosed with (presumed) lung cancer in 2020. We talk about the importance of tissue/pathologic diagnosis, the doctor-patient relationship, what we do with cell phone numbers (!), and how asking for help makes relationships stronger. Bess Siegal is a talented, intelligent, and savvy small business owner who has developed large-scale web applications, educational apps, and currently builds websites for authors and small businesses. She attended...
2023-03-0814 minCANCER BUZZPrioritizing a Multidisciplinary Team Approach in the Care of Patients with Small Cell Lung CancerBecause most cases of SCLC are diagnosed at advanced stages, it is rarely curable by the time of diagnosis. However, for some patients, treatment can improve quality of life. Multidisciplinary care coordination is especially important with aggressive cases of SCLC, as there may be several unique challenges to be addressed. CANCER BUZZ spoke to Ahmed Al-Hazzouri, MD, Medical Oncologist, Ryan Schroeder, MD, Pulmonologist, and Justin Wu, MD, Radiation Oncologist, from AdventHealth's Cancer Institute Waterman, Tavares, FL. Hear what impact a multidisciplinary team approach can have on patient experience and health outcomes. "The Lung Nodule Clinic is a...
2023-01-1712 min
Science with a TwistNo One Missed: Empowering Lung Cancer Patients with Biomarker Insights⚡ There's a diversity mismatch in the oncology workforce. One of the biggest challenges in the oncology space is a lack of diversity in the workforce. The population of the United States is very diverse, while the oncology field is not. Dr. Upal Basu Roy says, "We know that the United States is very diverse. As we speak, the population is very diverse, and we have about 12% African Americans in the population — about 18% who identify as Hispanic/Latinx — and 3% of the population who identify as American Indians and Alaska natives. But is that diversity reflected in the oncology workforce? Absolutely not. S...
2022-12-2229 minCANCER BUZZOptimizing SCLC Patient Outcomes Through Multidisciplinary Care CoordinationMany patients with SCLC face a high symptom burden, poor prognosis, and adherence challenges due to treatment-related adverse events, stigmatization, and emotional distress. Multidisciplinary care coordination and timely diagnosis are critical in the health outcomes of patients with SCLC. CANCER BUZZ spoke to Gustavo Cumbo-Nacheli, MD, Interventional Pulmonologist and Critical Care Medicine and Pulmonary Medicine Physician at Spectrum Health in Grand Rapids, MI. Hear how care coordination through a multidisciplinary team can improve patient experience and health outcomes. Gustavo Cumbo-Nacheli, MD Interventional Pulmonologist Critical Care Medicine and Pulmonary Medicine Physician Spectrum...
2022-12-1306 min
Navigating Cancer TOGETHERStage 4 NonSmoker Lung Cancer: It Can Happen to Anyone with Tiffany FagnaniTiffany was diagnosed with stage 4 non-small cell lung cancer that had spread to her brain at age 36. Prior to her diagnosis, Tiffany lived an active, healthy lifestyle and worked as a nurse. Never did she think that one day, she herself would become the patient that she had spent her career caring for. Throughout her diagnosis, Tiffany has learned to become her own best advocate and work with her healthcare team to find the best treatment for her specific type of lung cancer. In July 2020, Tiffany’s doctors declared her NED – no evidence of disease.
✨A few hi...
2022-11-3028 minCANCER BUZZEngaging Patients with Small Cell Lung Cancer in Clinical TrialsMany patients with SCLC have a high symptom burden, poor prognosis, adherence challenges due to treatment-related adverse events, stigmatization, and emotional distress. Clinical trials are taking place across the country for patients with all stages of small cell lung cancer. CANCER BUZZ spoke to David Waterhouse, MD, MPH, Medical Oncologist and Hematologist at the Dana-Farber Brigham Cancer Center, Milford Regional Medical Center in Milford, MA. Hear how to engage patients in clinical trials and address barriers. "Eighty-five percent (85%) of cancer care is being done in the community, not at academic centers such as ours. And so, you have...
2022-11-2209 minPeerView Clinical Pharmacology CME/CNE/CPE VideoDavid P. Carbone, MD, PhD - Gaining an Advantage Over NSCLC: How to Achieve the Greatest Benefit With Immunotherapy From Advanced to Early DiseaseGo online to PeerView.com/RGK860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Cancer immunotherapies in the form of anti–PD-1, anti–PD-L1, and anti–CTLA-4 immune checkpoint inhibitors (ICIs) have transformed the treatment of advanced and metastatic NSCLC without actionable genomic alterations, with a number of single-agent and combinatorial options available for clinical use. In light of demonstrably improved outcomes in the metastatic setting, ICIs are transitioning to earlier disease settings as part of perioperative neoadjuvant and/or adjuvant treatment strategies, which will likely result in reduced recurrence rates and more p...
2022-07-211h 44PeerView Heart, Lung & Blood CME/CNE/CPE Audio PodcastDavid P. Carbone, MD, PhD - Gaining an Advantage Over NSCLC: How to Achieve the Greatest Benefit With Immunotherapy From Advanced to Early DiseaseGo online to PeerView.com/RGK860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Cancer immunotherapies in the form of anti–PD-1, anti–PD-L1, and anti–CTLA-4 immune checkpoint inhibitors (ICIs) have transformed the treatment of advanced and metastatic NSCLC without actionable genomic alterations, with a number of single-agent and combinatorial options available for clinical use. In light of demonstrably improved outcomes in the metastatic setting, ICIs are transitioning to earlier disease settings as part of perioperative neoadjuvant and/or adjuvant treatment strategies, which will likely result in reduced recurrence rates and more p...
2022-07-211h 44PeerView Oncology & Hematology CME/CNE/CPE Video PodcastDavid P. Carbone, MD, PhD - Gaining an Advantage Over NSCLC: How to Achieve the Greatest Benefit With Immunotherapy From Advanced to Early DiseaseGo online to PeerView.com/RGK860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Cancer immunotherapies in the form of anti–PD-1, anti–PD-L1, and anti–CTLA-4 immune checkpoint inhibitors (ICIs) have transformed the treatment of advanced and metastatic NSCLC without actionable genomic alterations, with a number of single-agent and combinatorial options available for clinical use. In light of demonstrably improved outcomes in the metastatic setting, ICIs are transitioning to earlier disease settings as part of perioperative neoadjuvant and/or adjuvant treatment strategies, which will likely result in reduced recurrence rates and more p...
2022-07-211h 44PeerView Clinical Pharmacology CME/CNE/CPE Audio PodcastDavid P. Carbone, MD, PhD - Gaining an Advantage Over NSCLC: How to Achieve the Greatest Benefit With Immunotherapy From Advanced to Early DiseaseGo online to PeerView.com/RGK860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Cancer immunotherapies in the form of anti–PD-1, anti–PD-L1, and anti–CTLA-4 immune checkpoint inhibitors (ICIs) have transformed the treatment of advanced and metastatic NSCLC without actionable genomic alterations, with a number of single-agent and combinatorial options available for clinical use. In light of demonstrably improved outcomes in the metastatic setting, ICIs are transitioning to earlier disease settings as part of perioperative neoadjuvant and/or adjuvant treatment strategies, which will likely result in reduced recurrence rates and more p...
2022-07-211h 44PeerView Oncology & Hematology CME/CNE/CPE Audio PodcastDavid P. Carbone, MD, PhD - Gaining an Advantage Over NSCLC: How to Achieve the Greatest Benefit With Immunotherapy From Advanced to Early DiseaseGo online to PeerView.com/RGK860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Cancer immunotherapies in the form of anti–PD-1, anti–PD-L1, and anti–CTLA-4 immune checkpoint inhibitors (ICIs) have transformed the treatment of advanced and metastatic NSCLC without actionable genomic alterations, with a number of single-agent and combinatorial options available for clinical use. In light of demonstrably improved outcomes in the metastatic setting, ICIs are transitioning to earlier disease settings as part of perioperative neoadjuvant and/or adjuvant treatment strategies, which will likely result in reduced recurrence rates and more p...
2022-07-211h 44PeerView Heart, Lung & Blood CME/CNE/CPE Video PodcastDavid P. Carbone, MD, PhD - Gaining an Advantage Over NSCLC: How to Achieve the Greatest Benefit With Immunotherapy From Advanced to Early DiseaseGo online to PeerView.com/RGK860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Cancer immunotherapies in the form of anti–PD-1, anti–PD-L1, and anti–CTLA-4 immune checkpoint inhibitors (ICIs) have transformed the treatment of advanced and metastatic NSCLC without actionable genomic alterations, with a number of single-agent and combinatorial options available for clinical use. In light of demonstrably improved outcomes in the metastatic setting, ICIs are transitioning to earlier disease settings as part of perioperative neoadjuvant and/or adjuvant treatment strategies, which will likely result in reduced recurrence rates and more p...
2022-07-211h 44PeerView Internal Medicine CME/CNE/CPE Video PodcastDavid P. Carbone, MD, PhD - Gaining an Advantage Over NSCLC: How to Achieve the Greatest Benefit With Immunotherapy From Advanced to Early DiseaseGo online to PeerView.com/RGK860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Cancer immunotherapies in the form of anti–PD-1, anti–PD-L1, and anti–CTLA-4 immune checkpoint inhibitors (ICIs) have transformed the treatment of advanced and metastatic NSCLC without actionable genomic alterations, with a number of single-agent and combinatorial options available for clinical use. In light of demonstrably improved outcomes in the metastatic setting, ICIs are transitioning to earlier disease settings as part of perioperative neoadjuvant and/or adjuvant treatment strategies, which will likely result in reduced recurrence rates and more p...
2022-07-211h 44PeerView Internal Medicine CME/CNE/CPE Audio PodcastDavid P. Carbone, MD, PhD - Gaining an Advantage Over NSCLC: How to Achieve the Greatest Benefit With Immunotherapy From Advanced to Early DiseaseGo online to PeerView.com/RGK860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Cancer immunotherapies in the form of anti–PD-1, anti–PD-L1, and anti–CTLA-4 immune checkpoint inhibitors (ICIs) have transformed the treatment of advanced and metastatic NSCLC without actionable genomic alterations, with a number of single-agent and combinatorial options available for clinical use. In light of demonstrably improved outcomes in the metastatic setting, ICIs are transitioning to earlier disease settings as part of perioperative neoadjuvant and/or adjuvant treatment strategies, which will likely result in reduced recurrence rates and more p...
2022-07-211h 44
Talking SchmidtEpisode 49 - Amanda KouriAmanda Kouri is an inspirational lung cancer survivor. She was on a Patreon episode back in November and we have decided to share that with you now. She also brought us some rum!
Donate to the LUNGevity Foundation here: https://www.lungevity.org/
Please consider joining our Patreon page to hear more great episodes like this one. We post two per month there. Patreon.com/TalkingSchmidt
Follow Amanda:
Instagram: @amandakouri
Follow Eric:
Twitter: @TalkingSchmidt
Instagram: @TalkingSchmidt
TikTok: @TikTalkingSchmidt
Follow Greg:
Twitter: @GregBurmeister
Instagram: @GregHello
TikTok: @GregBurmeister
2022-07-0732 minPeerView Clinical Pharmacology CME/CNE/CPE Audio PodcastStephen V. Liu, MD - Find the Targets, Treat With Precision: Modern Principles and New Advances in Biomarker-Driven Lung Cancer CareGo online to PeerView.com/UTP860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In the modern era of precision oncology, comprehensive biomarker profiling of complex and heterogeneous tumors such as non–small cell lung cancer (NSCLC) is essential for determining the best therapeutic approach for each patient. Patients with lung cancer who have targetable genomic alterations can derive remarkable benefit from targeted therapies, and the list of relevant targets and matched therapies continues to expand, including in early-stage disease settings. Unfortunately, molecular testing rates remain woefully inadequate, and even when testing is...
2022-06-301h 37PeerView Heart, Lung & Blood CME/CNE/CPE Audio PodcastStephen V. Liu, MD - Find the Targets, Treat With Precision: Modern Principles and New Advances in Biomarker-Driven Lung Cancer CareGo online to PeerView.com/UTP860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In the modern era of precision oncology, comprehensive biomarker profiling of complex and heterogeneous tumors such as non–small cell lung cancer (NSCLC) is essential for determining the best therapeutic approach for each patient. Patients with lung cancer who have targetable genomic alterations can derive remarkable benefit from targeted therapies, and the list of relevant targets and matched therapies continues to expand, including in early-stage disease settings. Unfortunately, molecular testing rates remain woefully inadequate, and even when testing is...
2022-06-301h 37PeerView Oncology & Hematology CME/CNE/CPE Video PodcastStephen V. Liu, MD - Find the Targets, Treat With Precision: Modern Principles and New Advances in Biomarker-Driven Lung Cancer CareGo online to PeerView.com/UTP860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In the modern era of precision oncology, comprehensive biomarker profiling of complex and heterogeneous tumors such as non–small cell lung cancer (NSCLC) is essential for determining the best therapeutic approach for each patient. Patients with lung cancer who have targetable genomic alterations can derive remarkable benefit from targeted therapies, and the list of relevant targets and matched therapies continues to expand, including in early-stage disease settings. Unfortunately, molecular testing rates remain woefully inadequate, and even when testing is...
2022-06-301h 37PeerView Heart, Lung & Blood CME/CNE/CPE Video PodcastStephen V. Liu, MD - Find the Targets, Treat With Precision: Modern Principles and New Advances in Biomarker-Driven Lung Cancer CareGo online to PeerView.com/UTP860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In the modern era of precision oncology, comprehensive biomarker profiling of complex and heterogeneous tumors such as non–small cell lung cancer (NSCLC) is essential for determining the best therapeutic approach for each patient. Patients with lung cancer who have targetable genomic alterations can derive remarkable benefit from targeted therapies, and the list of relevant targets and matched therapies continues to expand, including in early-stage disease settings. Unfortunately, molecular testing rates remain woefully inadequate, and even when testing is...
2022-06-301h 37PeerView Clinical Pharmacology CME/CNE/CPE VideoStephen V. Liu, MD - Find the Targets, Treat With Precision: Modern Principles and New Advances in Biomarker-Driven Lung Cancer CareGo online to PeerView.com/UTP860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In the modern era of precision oncology, comprehensive biomarker profiling of complex and heterogeneous tumors such as non–small cell lung cancer (NSCLC) is essential for determining the best therapeutic approach for each patient. Patients with lung cancer who have targetable genomic alterations can derive remarkable benefit from targeted therapies, and the list of relevant targets and matched therapies continues to expand, including in early-stage disease settings. Unfortunately, molecular testing rates remain woefully inadequate, and even when testing is...
2022-06-301h 37
PeerView Immunology & Transplantation CME/CNE/CPE Audio PodcastStephen V. Liu, MD - Find the Targets, Treat With Precision: Modern Principles and New Advances in Biomarker-Driven Lung Cancer CareGo online to PeerView.com/UTP860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In the modern era of precision oncology, comprehensive biomarker profiling of complex and heterogeneous tumors such as non–small cell lung cancer (NSCLC) is essential for determining the best therapeutic approach for each patient. Patients with lung cancer who have targetable genomic alterations can derive remarkable benefit from targeted therapies, and the list of relevant targets and matched therapies continues to expand, including in early-stage disease settings. Unfortunately, molecular testing rates remain woefully inadequate, and even when testing is...
2022-06-301h 37PeerView Oncology & Hematology CME/CNE/CPE Audio PodcastStephen V. Liu, MD - Find the Targets, Treat With Precision: Modern Principles and New Advances in Biomarker-Driven Lung Cancer CareGo online to PeerView.com/UTP860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In the modern era of precision oncology, comprehensive biomarker profiling of complex and heterogeneous tumors such as non–small cell lung cancer (NSCLC) is essential for determining the best therapeutic approach for each patient. Patients with lung cancer who have targetable genomic alterations can derive remarkable benefit from targeted therapies, and the list of relevant targets and matched therapies continues to expand, including in early-stage disease settings. Unfortunately, molecular testing rates remain woefully inadequate, and even when testing is...
2022-06-301h 37
PeerView Immunology & Transplantation CME/CNE/CPE Video PodcastStephen V. Liu, MD - Find the Targets, Treat With Precision: Modern Principles and New Advances in Biomarker-Driven Lung Cancer CareGo online to PeerView.com/UTP860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In the modern era of precision oncology, comprehensive biomarker profiling of complex and heterogeneous tumors such as non–small cell lung cancer (NSCLC) is essential for determining the best therapeutic approach for each patient. Patients with lung cancer who have targetable genomic alterations can derive remarkable benefit from targeted therapies, and the list of relevant targets and matched therapies continues to expand, including in early-stage disease settings. Unfortunately, molecular testing rates remain woefully inadequate, and even when testing is...
2022-06-301h 37
Relationships & Revenue PodcastSupporting a Loved One with CancerIf you or someone you know has a loved one fighting cancer but you don't know how to support them, this episode is for you. John talks about his mother's battle with cancer and shares a few things that will help you support those you love and care about who have cancer. Listen to this episode to learn more: [01:25] - Why John is doing this episode [02:47] - How Owen and Theresa Hemsath helped John [04:16] - Tips to support those you love who are battling cancer [05:17] - Simply listening to...
2022-06-0122 min
Man Up to CancerReasons to HOPE, with 9-year lung cancer survivor Buddy CutlerFor today's episode, I was honored to spend time talking to Ed “Buddy” Cutler, who has been thriving for nearly a decade with metastatic lung cancer. Yep, Buddy was diagnosed nine years ago. Thanks to his self-advocacy and a phase one clinical trial, Buddy has far outlived his prognosis. He has become a beloved advocate for cancer organizations, including the LUNGevity Foundation. He has also made a lot of friends through Moffitt Cancer Center. A native of Tampa, Fla., Buddy is a proud father and grandfather, a US Navy veteran, and a (mostly) retired CPA and...
2022-04-2945 min
Pleural Space | Conversations in Lung CancerPatients Are Looking For a Community: How Lung Cancer Advocacy WorksFor 2022's National Patient Recognition Week, Elridge Proctor of the Go2 Foundation sits down with Heidi and Pierre Onda of the White Ribbon Project and Nichelle Stigger from LUNGevity to discuss how they went from patient to patient advocates and ways those without lung cancer can use their voices for change.
Elridge Proctor, MPA, is the Senior Director for Government Affairs and Public Policy at the Go2 Foundation for Lung Cancer, with over 15 years of experience in patient advocacy and non-profit work. Heidi Onda, MS, is a health educator and fitness trainer as well as a lung...
2022-01-3132 min
Precision Medicine PodcastLUNGevity Leaders Discuss Their Commitment to Educating Lung Cancer Patients About the Importance of Biomarker TestingIn this Precision Medicine Podcast episode, we are joined by Dr. Belinda King-Kallimanis, Director of Patient-Focused Research at LUNGevity—an organization that brings together research, education and support services for patients and caregivers in the lung cancer community—and Nichelle Stigger, LUNGevity board member and lung cancer survivor. They sat down with us to discuss everything from the importance of patient-friendly language in lung cancer to discrepancies in access to biomarker testing and what LUNGevity is doing to improve the status quo. Read the full summary and listen here.
2022-01-1140 minCANCER BUZZBiomarker Testing AdvocacyBiomarker testing is an important part of precision medicine; however, many commercial health plans and state Medicaid programs lack adequate coverage, which can have life-threatening consequences for patients with cancer who could benefit from biomarker testing. Some good news: health insurance coverage advocates have seen "wins" in three states in 2021: California, Illinois, and Louisiana. In this episode, we spoke with two healthcare advocates who explore these recent policy changes as it relates to biomarker testing. Tune in to find out what these legislative changes mean for your program or practice—and discover approaches to advise policymakers in you...
2021-12-0721 minPleural Space | Conversations in Lung CancerStigma and Nihilism in Lung Cancer Care and Control (Part 1)"The Power of Partnerships” limited podcast series will feature conversations currently happening in the world of lung cancer with the people pushing the field into the future.
Dr. Jamie Studts and patient advocates Jill Feldman and Jim Pantelas discuss stigma surrounding lung cancer from internal and external sources and the work being done to combat stigma.
Jamie L. Studts, PhD, FSBM, is a Professor of Medical Oncology at the University of Colorado School of Medicine and Scientific Director of Behavioral Oncology. Dr. Studts also serves as the Chair for the NLCRT’s Surv...
2021-11-2237 min
CANCER BUZZPrecision Medicine DisparitiesWhile the identification of actionable biomarkers is fueling huge advancements in precision medicine and targeted therapies for the management of non-small cell lung cancer (NSCLC), access to these tests and associated therapies are not consistent throughout the healthcare system and have the potential to worsen existing health disparities. Hear from two authors of an ACCC/LUNGevity Foundation study that identified key areas of clinician need related to biomarker testing in NSCLC, including increased guideline familiarity, practical applications of guideline-concordant testing, enhancing patient-clinician discussions and education, and access to appropriate clinical trials. Guests: Christopher S...
2021-11-1115 min
Groove with PortiaNot Longevity, Lungevity!I thought my heart stopped when I read a sign at the hospital that Lung Cancer is the number one killer for both men and women. Let that sink in. As most of you know, my mother survived her battle with lung cancer, but many individuals do not. What will it take for individuals to care more about their lung health? On this episode of Groove with Portia, I am joined by Alessandra Crish from the American Lung Association of Ohio and also my own mother who shares her story of battling lung cancer. Tune in to hear the personal...
2021-11-0358 minPeerView Internal Medicine CME/CNE/CPE Video PodcastStephen V. Liu, MD - Tracking All the Targets in Genomically Altered NSCLC: Everything You Need to Know About Biomarker Testing and TreatmentGo online to PeerView.com/EYW860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Comprehensive biomarker profiling of complex and heterogeneous tumors such as non–small cell lung cancer (NSCLC) is crucial for determining the best therapeutic approach for each patient. In metastatic NSCLC, the number of molecular alterations that have FDA-approved matched therapies has been rapidly growing. The first targeted therapy has received regulatory approval in the adjuvant setting of early-stage disease, and there are many more emerging targets against which novel therapies have shown great promise in clinical trials. Patients wi...
2021-09-301h 39PeerView Oncology & Hematology CME/CNE/CPE Video PodcastStephen V. Liu, MD - Tracking All the Targets in Genomically Altered NSCLC: Everything You Need to Know About Biomarker Testing and TreatmentGo online to PeerView.com/EYW860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Comprehensive biomarker profiling of complex and heterogeneous tumors such as non–small cell lung cancer (NSCLC) is crucial for determining the best therapeutic approach for each patient. In metastatic NSCLC, the number of molecular alterations that have FDA-approved matched therapies has been rapidly growing. The first targeted therapy has received regulatory approval in the adjuvant setting of early-stage disease, and there are many more emerging targets against which novel therapies have shown great promise in clinical trials. Patients wi...
2021-09-301h 39PeerView Clinical Pharmacology CME/CNE/CPE VideoStephen V. Liu, MD - Tracking All the Targets in Genomically Altered NSCLC: Everything You Need to Know About Biomarker Testing and TreatmentGo online to PeerView.com/EYW860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Comprehensive biomarker profiling of complex and heterogeneous tumors such as non–small cell lung cancer (NSCLC) is crucial for determining the best therapeutic approach for each patient. In metastatic NSCLC, the number of molecular alterations that have FDA-approved matched therapies has been rapidly growing. The first targeted therapy has received regulatory approval in the adjuvant setting of early-stage disease, and there are many more emerging targets against which novel therapies have shown great promise in clinical trials. Patients wi...
2021-09-301h 39PeerView Internal Medicine CME/CNE/CPE Audio PodcastStephen V. Liu, MD - Tracking All the Targets in Genomically Altered NSCLC: Everything You Need to Know About Biomarker Testing and TreatmentGo online to PeerView.com/EYW860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Comprehensive biomarker profiling of complex and heterogeneous tumors such as non–small cell lung cancer (NSCLC) is crucial for determining the best therapeutic approach for each patient. In metastatic NSCLC, the number of molecular alterations that have FDA-approved matched therapies has been rapidly growing. The first targeted therapy has received regulatory approval in the adjuvant setting of early-stage disease, and there are many more emerging targets against which novel therapies have shown great promise in clinical trials. Patients wi...
2021-09-301h 38PeerView Clinical Pharmacology CME/CNE/CPE Audio PodcastStephen V. Liu, MD - Tracking All the Targets in Genomically Altered NSCLC: Everything You Need to Know About Biomarker Testing and TreatmentGo online to PeerView.com/EYW860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Comprehensive biomarker profiling of complex and heterogeneous tumors such as non–small cell lung cancer (NSCLC) is crucial for determining the best therapeutic approach for each patient. In metastatic NSCLC, the number of molecular alterations that have FDA-approved matched therapies has been rapidly growing. The first targeted therapy has received regulatory approval in the adjuvant setting of early-stage disease, and there are many more emerging targets against which novel therapies have shown great promise in clinical trials. Patients wi...
2021-09-301h 38PeerView Heart, Lung & Blood CME/CNE/CPE Video PodcastStephen V. Liu, MD - Tracking All the Targets in Genomically Altered NSCLC: Everything You Need to Know About Biomarker Testing and TreatmentGo online to PeerView.com/EYW860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Comprehensive biomarker profiling of complex and heterogeneous tumors such as non–small cell lung cancer (NSCLC) is crucial for determining the best therapeutic approach for each patient. In metastatic NSCLC, the number of molecular alterations that have FDA-approved matched therapies has been rapidly growing. The first targeted therapy has received regulatory approval in the adjuvant setting of early-stage disease, and there are many more emerging targets against which novel therapies have shown great promise in clinical trials. Patients wi...
2021-09-301h 39PeerView Oncology & Hematology CME/CNE/CPE Audio PodcastStephen V. Liu, MD - Tracking All the Targets in Genomically Altered NSCLC: Everything You Need to Know About Biomarker Testing and TreatmentGo online to PeerView.com/EYW860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Comprehensive biomarker profiling of complex and heterogeneous tumors such as non–small cell lung cancer (NSCLC) is crucial for determining the best therapeutic approach for each patient. In metastatic NSCLC, the number of molecular alterations that have FDA-approved matched therapies has been rapidly growing. The first targeted therapy has received regulatory approval in the adjuvant setting of early-stage disease, and there are many more emerging targets against which novel therapies have shown great promise in clinical trials. Patients wi...
2021-09-301h 38PeerView Heart, Lung & Blood CME/CNE/CPE Audio PodcastStephen V. Liu, MD - Tracking All the Targets in Genomically Altered NSCLC: Everything You Need to Know About Biomarker Testing and TreatmentGo online to PeerView.com/EYW860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Comprehensive biomarker profiling of complex and heterogeneous tumors such as non–small cell lung cancer (NSCLC) is crucial for determining the best therapeutic approach for each patient. In metastatic NSCLC, the number of molecular alterations that have FDA-approved matched therapies has been rapidly growing. The first targeted therapy has received regulatory approval in the adjuvant setting of early-stage disease, and there are many more emerging targets against which novel therapies have shown great promise in clinical trials. Patients wi...
2021-09-301h 38
NCSL PodcastsNew Era of Cancer Diagnosis and Treatment | OAS Episode 138One of the most promising areas of cancer treatment involves identifying the cancer a person has and using therapies targeted at just that cancer. This field of precision medicine or targeted medicine is not well understood by most lawmakers or the general public.
On the podcast to discuss this emerging field is Dr. Carl Morrison, a molecular biologist and pathologist who is the senior vice president of Scientific Development and Integrative Medicine at the Roswell Park Comprehensive Cancer Center in Buffalo, N.Y. He is one of the nation’s leading researchers in the field.
Ou...
2021-08-0819 min
SoundOffEp 146 - LUNGevity and the No One Missed CampaignOn this episode of SoundOff, Jams is joined by friend and fellow lung cancer warrior Nichelle Stigger as they talk about their involvement with LUNGevity's No One Missed campaign and the importance of biomarker testing in Non Small Cell Lung Cancer (NSCLC). Biomarker testing played a significant role in the treatment of them both but there are still patients who are not afforded the opportunity to have this done.
Please like WJMS Radio on Facebook, Instagram and Twitter!
For new content, check out SoundOff every Saturday at 12pm EST on WJMS Radio!
We a...
2021-06-0541 min
Heme ReviewInterview With A Stage 4 Lung Cancer Survivor (Jill Hamer-Wilson)Video version of this interview: https://youtu.be/oLe9UdL-qIk
Jill's Blog: https://throughthevalley.ca
White Ribbon Project: https://twitter.com/TheWRP4LC
LUNGevity Foundation: https://lungevity.org
GO2 Foundation: https://go2foundation.org
Lung Cancer Canada: https://www.lungcancercanada.ca
Lung Foundation Australia: https://lungfoundation.com.au
Lung Cancer Europe (LUCe): https://www.lungcancereurope.eu
Tweet me: https://www.twitter.com/hemereview
IG me: https://www.instagram.com/hemereview
FB me: https://www.facebook.com...
2021-03-3025 min
What‘s Happalachenin‘?: An Appalachian PodcastJackie O's Brewery - Art OestrikeThe guys talk with the founder and president of Jackie O's Brewery, Art Oestrike about his business's history, small business in Appalachia, and so much more! John Isner of Appodlachia also joins us for our #DrinkToThat Segment. So crack open a cold one and enjoy another great conversation with a couple more fantastic Appalachians.
We encourage you to research and make a donation to the LUNGevity Foundation! #ChugginForCharity
Also check out Jackie O's website to learn about their entire operation and the phenomenal list of beers they craft!
2021-01-1056 min
"Verse of the day" Ministry Podcast"Verse of the day" Ministry Podcast Pop Up Episode Psalms 95:6(NIV) with a surprise co host Ronald " The Good Rev" SeegersLIKE ! SUBSCRIBE ! SHARE ! PARTICIPATE ! AND SPREAD THE GOSPEL AROUND THE WORLD ! "Verse of the day" Psalms 95: 6 (NIV) www.bible.com www.biblegateway.com Homework is always the book and the chapter for the day Psalms 95 Please give to the the Verse of the day Ministry..Give to the charities LUNGEVITY https://lungevity.org/, ProLiteracy https://proliteracy.org/ and Blind Cat Rescue https://blindcatrescue.com/ ...... Click on the links or copy and paste the link address..... for easy access the charities info is on buttons on the link >>https://linktr.ee/wandasncredible. To be a blessing to...
2020-11-2912 min
You’re A Knockout!#8: Why I Stand Up To Lung CancerIn this episode, I talk about my nonprofit work with LUNGevity, my dad’s short but incredibly brave battle with lung cancer, and what it’s like living with grief. I hope if you’re living with grief that this will help you feel a little more seen. I got your back Knockout!
2020-11-181h 39
Healthcare UnfilteredEpisode 6: Advocacy in a Time of Uncertainty: Jill Feldman’s Ongoing Battle With Lung CancerJill Feldman (@jillfeldman4), lung cancer survivor and advocate, shares her familial history of lung cancer that drove her to advocacy work long before her own diagnosis of EGFR-positive disease, as well as her treatment courses with erlotinib and subsequent SBRT for many years before osimertinib. Jill then describes her “journey” in advocacy, beginning with self-advocacy and the LUNGevity Foundation, independent research advocacy and representing lung cancer patients, and co-founding the EGFR Resisters (@EGFRResisters) – a group of EGFR-positive patients who are resistant to targeted treatment. Her message for clinicians and scientists is to start thinking of patients as partners in resear...
2020-11-171h 04
We Are UnstoppableEmily DanielsEmily Daniels arrived at the E.R. short of breath while pregnant with her second child to discover she had Stage IV lung cancer. She had never smoked a day in her life.
Emily’s diagnosis belongs to more than 50% of lung cancer cases without a definitive explainable cause. Did you know that lung cancer in non-smokers might be caused by exposure to radon, secondhand smoke, air pollution, and even wok smoke?
Had Emily been diagnosed 10 years ago, she would not be alive to tell us this story. In this episode, she is joined by her husband, Brian Daniels - form...
2020-11-0429 minCANCER BUZZFinancial Barriers to Biomarker TestingThe advent of biomarker testing has brought targeted cancer treatment to more patients than ever before. However, these tests require a collaborative effort from a number of specialists—and that means a high price tag. Additionally, private payers have different reimbursement structures that change frequently, resulting in lengthy pre-authorization periods. On this episode of CANCER BUZZ, we speak to two financial navigators about their roles helping patients and providers understand the options available to patients in need of biomarker testing. Guests: Rifeta Kajdic, Program Manager, Oncology Service Line, St. Luke's Cancer Institute Arnela Kajdic-Tarantino, BMT...
2020-09-2923 min
Hope With Answers: Living With Lung Cancer08.3 - How did lung cancer groups rally to inform patients during COVID-19Living with lung cancer comes with many challenges, especially during the COVID-19 era. Unfortunately, information about how COVID-19 affects lung cancer patients is hard to come by. Stepping into this void, lung cancer advocacy groups have worked together to produce consistent resources with the latest learnings, updates, and information to help those living with lung cancer during COVID-19.
Guests
Janet Freeman-Daily is a lung cancer patient and activist who brings her engineering background to research advocacy.
Upal Basu Roy, PhD, MPH, LUNGevity Vice President of Research. Dr. Roy is responsible for setting strategy...
2020-08-1329 min
Hope With Answers: Living With Lung Cancer08.3 - How did lung cancer groups rally to inform patients during COVID-19Living with lung cancer comes with many challenges, especially during the COVID-19 era. Unfortunately, information about how COVID-19 affects lung cancer patients is hard to come by. Stepping into this void, lung cancer advocacy groups have worked together to produce consistent resources with the latest learnings, updates, and information to help those living with lung cancer during COVID-19.GuestsJanet Freeman-Daily is a lung cancer patient and activist who brings her engineering background to research advocacy.Upal Basu Roy, PhD, MPH, LUNGevity Vice President of Research. Dr. Roy is responsible for setting strategy and overseeing LUNGevity’s scientific research awards programs an...
2020-08-1329 min
Lung Cancer ConsideredWhat Patients Need to Know About Lung Cancer Research in the Era of COVID-19The newest episode of Lung Cancer Considered, the IASLC's official podcast program, features patient advocates and lung cancer researchers on what patients need to know about lung cancer research in the era of COVID-19. This episode features a conversation between Janet Freeman-Daily, writer, lung cancer patient, advocate and Twitter chat moderator of the Lung Cancer Social Media chat (#LCSMchat); Jill Feldman, lung cancer advocate and patient; Dr. Alice Berger, assistant professor of human biology at the Fred Hutchinson Cancer Research Center; Dr. Christine Lovly, associate professor of medicine, division of Hematology and Oncology and Ingram Associate Professor of Cancer Research...
2020-05-2640 min
Out of Patients with Matthew ZacharyCOVID-19 and Lung Cancer: Stigma, Advocacy, and the Latest ResearchMatthew and Andrew welcome cancer survivors Nina Beaty, Creator, The EmPat Cancer Project, and Katie Brown, Vice President of Support and Survivorship Programs at The LUNGevity Foundation, to opine on the current status of lung cancer in America and around the world. Issues of stigma, the increasing prevalence in young women, new treatment options, and how to navigate the COVID-19 pandemic are just some of the pressing topics we cover in this crucial episode.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.
2020-05-2135 minLung Cancer ConsideredCOVID-19 Facts and Impacts for the Lung Cancer CommunityThis episode features Janet Freeman- Daily, writer, lung cancer patient, advocate and Twitter chat moderator of the Lung Cancer Social Media chat (#LCSMchat), she is joined by Dr. Amy Moore, Director of Science and Research at the Go2 Foundation, Dr. Upal Basu Roy, Vice President of Research at LUNGevity Foundation, and Dr. Lecia Sequist, Director of Center for Innovation and Early Cancer Detection at Massachusetts General Hospital and the Landry Family Associate Professor of Medicine at Harvard Medical School. Together they discuss the impact of the COVID-19 epidemic on lung cancer patients and healthcare providers.
2020-03-3133 min
Out of Patients with Matthew ZacharyCOVID-19 Explainer: Lung Cancer and the PandemicOn today's show, Matthew discusses COVID-19 and its impact on the cancer community with Michael Parisi (CEO at Guidemark), Andrea Ferris (President and Chairman of Lungevity) and Andrew MacDowell (OffScrip Media Co-Founder and COO.) The world is burning, and we have to keep it spinning. The need is incalculable. The resources are scarce. We need hope, but more importantly, we need FACTS.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.
2020-03-2424 min
FL Man WeeklyElders, Cops, and ShowersIn this episode of FL Man Weekly Corn and Stubbs discuss why it's important to respect your elders, playing cops and robbers shouldn't continue as an adult, and everyone needs to bathe?
They review the Sunshine State FL Lager, Amber Lager from Florida Beer Co (https://floridabeer.com).
The Florida Feels story highlights a man who wants all men to know breast cancer doesn't just occur in women (https://makingstrides.ascevents.org).
Finally, continuing our effort to bring awareness to the top cancers affecting women, they bring awareness to Lung Cancer.
...
2019-10-2133 min
WTFeminine! Conversations That Get Down to the Nitty Gritty with Women Like UsWill You Choose Mud or Stars? with Gina HollenbeckGina Hollenbeck is a mom & lung cancer WARRIOR! Kim met Gina back in 2016 when Kim started the WARRIOR project which is a photo shoot that celebrates women that are currently battling cancer as well as those who are now in remission. Since then, the two have become friends who continue to love and support each other. In this episode, Kim and Gina chat about selling most of your belongings and moving to a new country with two young boys in tow. Gina shares the ups and downs of this experience and what she learned about...
2018-12-191h 13
Community D.C.LUNGevity Foundation 2018Lung Cancer is sneaky and hard to detect. Many people with Lung Cancer are already at ‘stage 4’ by the time they are diagnosed. The key is early detection. Learn about LUNGevity Foundation history and mission and get details about the upcoming Breathe Deep DC Walk. Great cause, awesome event location on the National Mall.See omnystudio.com/listener for privacy information.
2018-10-1214 min
Poppin' BottlesNUUN Electrolyte Drink Tablets with Erin ElmoreElectrolytes enthusiast Erin Elmore shares about running for LUNGevity, married life, and the movie Out Of Sight. Rob finally lets us know if he will run a marathon and Josh helps makes the podcast AMSR compliant.
Erin Breeze
1.5 oz Coconut Rum
5 oz Coconut Water
1 oz Pineapple Juice
5 Crushed Cherry-Lime Nuun Ice Cubes
.5 oz Lime Juice
Top with Cherry-Lime Nuun
Visit our Merch closet at https://poppinbottles.threadless.com!
2018-09-1354 min
Community D.C.Lung Cancer - LUNGevity OrganizationLUNGevity’s Becky Bull talks about lung cancer symptoms, research, treatments & renewed optimism for a cure.See omnystudio.com/listener for privacy information.
2017-11-2813 min
Faith Health & HomeHighlighting the Caregiver’s Role in Navigating Lung CancerKatie Brown, Vice President, Support and Survivorship Programs, LUNGevity, and Anita Logsdon, RN, BSN, MSN, OSN, Oncology Hematology Care joined me to discuss the unique challenges and experiences of caregivers for people fighting such a devastating disease as lung cancer in light of findings from a NEW national survey of caregivers of people with lung cancer. They also shared advice on much needed resources and support.
2016-11-1007 min
In The Author's VoiceIn The Author's Voice: Lung Cancer(American Cancer Society)November is both Lung Cancer Awareness Month and National Family Caregivers Month. According to the American Cancer Society, lung cancer is the leading cause of cancer death among men and women.In the edition of In The Author's Voice, WSIU's Jeff Williams talks with Anita Logsdon, a treatment suite nurse with Oncology Hematology Care; and Katie Brown, Vice President for Support and Survivorship Programs with LUNGevity, a lung-cancer research and advocacy group about the disease and its impact on society.More information on Lung Cancer and support for ca...
2016-11-0411 min
The Stupid Cancer ShowSTUPID LUNG CANCER - PART 2In this episode, we welcome Dr. Barbara Gitlitz (Principal Investigator of GoYLC), and young adult lung cancer survivors Sandy Jauregui and Jeff Julian to discuss the genomics of young adult lung cancer, clinical trials and targeted therapies. Survivor/Advocate spotlight on Katie Brown (VP, Survivorship, LUNGEVITY)
See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.
2015-06-161h 06The Stupid Cancer ShowSTUPID LUNG CANCER!Lung cancer is a bitch. What's worse, more and more non-smoking young adults are getting diagnosed each year. What's up with that? Join us as we welcome Katie Brown (Director of Support and Advocacy at LUNGevity Foundation), Dr. Lynne Eldridge (author/speaker/lung cancer specialist) and LC survivor Kim Wieneke. Author David Tabatsky ("Write For Life") in the advocvacy spotlight.
See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.
2013-11-051h 03The Stupid Cancer ShowSTUPID LUNG CANCERSURVIVOR SPOTLIGHT
MATTHEW HIZNAY
Young Adult Survivor, Lung Cancer
Second Year Med Student
University of Toldeo
NATHAN PENNELL, MD, PhD
Board Certified Oncologist
Taussig Cancer Center
Cleveland Clinic
KATE BROWN
Director of Support and Advocacy
LUNGevity Foundation
See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.
2012-03-131h 11The Stupid Cancer ShowSTUPID LUNG CANCERADVOCATE SPOTLIGHT
MEGHAN ROGERS
Bereaved Young Adult Cancer Advocate
President
National Collegiate Cancer Foundation
KAY COFRANCESCO
Director of Advocacy Relations
Lung Cancer Alliance
BETH STERN
Executive Director
LUNGevity Foundation
See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.
2010-10-051h 16